Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia

Friday, September 23, 2022 1 min read

Key Takeaway: Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia

Full Press Release Details

Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia.